Bacille Calmette-Guérin/DNAhsp65 prime-boost is protective against diabetes in non-obese diabetic mice but not in the streptozotocin model of type 1 diabetes

Clinical and Experimental Immunology

Volumn 173, Issue 3, 2013, Pages 430-437

  Da Rosa, L C ^a   Chiuso Minicucci, F ^a   Zorzella Pezavento, S F G ^a   Franca T G D ^a   Ishikawa, L L W ^a   Colavite, P M ^a   Balbino, B ^a   Tavares, L C B ^a   Silva, C L ^b   Marques, C ^c   Ikoma, M R V ^c   Sartori, A ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c Amaral Carvalho Hospital   (Brazil)

Author keywords

BCG; Hsp65; Immunomodulation; NOD mice; Type 1 diabetes

Indexed keywords

BCG VACCINE; DNA VACCINE; PVAXHSP65 VACCINE; STREPTOZOCIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BCG VACCINATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HYPERGLYCEMIA; IMMUNOMODULATION; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SPLEEN; WEIGHT GAIN;

BCG; HSP65; IMMUNOMODULATION; NOD MICE; TYPE 1 DIABETES;

ANIMALS; BCG VACCINE; CYTOKINES; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; FEMALE; ISLETS OF LANGERHANS; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED NOD; STREPTOZOCIN; T-LYMPHOCYTES, REGULATORY;

EID: 84881512633     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12140     Document Type: Article

References (35)

1. Cabrera SM, Rigby MR, Mirmir RG. Targeting regulatory T cells in the treatment of type 1 diabetes mellitus. Curr Mol Med 2012; 12:1261-1272.
2. Maiese K, Shang YC, Chong ZZ, Hou J. Diabetes mellitus: channeling care through cellular discovery. Curr Neurovasc Res 2010; 7:59-64.
3. Wood SC, Rao TD, Frey AB. Multidose streptozotocin induction of diabetes in BALB/c By mice induces a T cell proliferation defect in thymocytes which is reversible by interleukin-4. Cell Immunol 1999; 192:1-12.
4. Rees DA, Alcolado JC. Animal models of diabetes mellitus. Diabet Med 2005; 22:359-370.
5. Aoki CA, Borchers AT, Ridgway WM, Keen CL, Ansari AA, Gershwin ME. NOD mice and autoimmunity. Autoimmun Rev 2005; 4:373-379.
6. Yang Y, Santamaria P. Lessons on autoimmune diabetes from animal models. Clin Sci (Lond) 2006; 110:627-639.
7. Driver JP, Serreze DV, Chen YG. Mouse models for the study of autoimmune type 1 diabetes: a NOD to similarities and differences to human disease. Semin Immunopathol 2011; 33:67-87.
8. Jäger A, Kuchroo VK. Effector and regulatory T-cell subsets in autoimmunity and tissue inflammation. Scand J Immunol 2010; 72:173-184.
9. van Eden W, van der Zee R, Prakken B. Heat-shock proteins induce T-cell regulation of chronic inflammation. Nat Rev Immunol 2005; 5:318-330.
10. Nicholas D, Odumosu O, Landridge WH. Autoantigen based vacines for type 1 diabetes. Discov Med 2011; 11:293-301.
11. Woodland DL. Jump-starting the immune system: prime-boosting comes of age. Trends Immunol 2004; 25:98-104.
12. Baik SH, Park IB, Choi KM etal. BCG vaccine prevents insulitis in low dose streptozotocin-induced diabetic mice. Diabetes Res Clin Pract 1999; 46:91-97.
13. Qin HY, Chaturvedi P, Bhagirath S. In vivo apoptosis of diabetogenic T cells in NOD mice by IFN-γ/TNF-α. Int Immunol 2004; 16:1723-1732.
14. Santos Junior RR, Sartori A, Bonato VL etal. Immune modulation induced by tuberculosis DNA vaccine protects non-obese diabetic mice from diabetes progression. Clin Exp Immunol 2007; 149:570-578.
15. Zorzella-Pezavento SF, Chiuso-Minicucci F, França TG etal. Immunization with pVAXhsp65 decreases inflammation and modulates immune response in experimental encephalomyelitis. Neuroimmunomodulation 2010; 17:287-297.
16. Chen W, Xie A, Chan L. Mechanistic basis of immunotherapies for type 1 diabetes mellitus. Transl Res 2013; 161:217-229.
17. Wieten L, van der Zee R, Spiering R etal. A novel heat-shock protein coinducer boosts stress protein Hsp70 to activate T cell regulation of inflammation in autoimmune arthritis. Arthritis Rheum 2010; 62:1026-1035.
18. Quintana FJ, Carmi P, Mor F, Cohen IR. DNA fragments of the human 60-kDa heat shock protein (HSP60) vaccinate against adjuvant arthritis: identification of a regulatory HSP60 peptide. J Immunol 2003; 171:3533-3541.
19. Santos Junior RR, Sartori A, Lima DS etal. DNA vaccine containing the mycobacterial hsp65 gene prevented insulitis in MLD-STZ diabetes. J Immune Based Ther Vaccines 2009; 7:4.
20. Borges TJ, Wieten L, van Herwijnen MJ etal. The anti-inflammatory mechanisms of Hsp70. Front Immunol 2012; 3:95.
21. Tonkin DR, Haskins K. Regulatory T cells enter the pancreas during suppression of type 1 diabetes and inhibit effector T cells and macrophages in a TGF-β-dependent manner. Eur J Immunol 2009; 39:1313-1322.
22. Szebeni A, Prohászka Z, Buzás E, Falus A, Kecskeméti V. Effects of vaccination with heat shock proteins on streptozotocin induced diabetes in histidine decarboxylase knockout mice. Inflamm Res 2008; 57:178-182.
23. Thayer TC, Wilson SB, Mathews CE. Use of nonobese diabetic mice to understand human type 1 diabetes. Endocrinol Metab Clin North Am 2010; 39:541-561.
24. Chaparro RJ, Dilorenzo TP. An update on the use of NOD mice to study autoimmune (Type 1) diabetes. Exp Rev Clin Immunol 2010; 6:939-955.
25. Sgouroudis E, Piccirillo CA. Control of type 1 diabetes by CD4+Foxp3+ regulatory T cells: lessons from mouse models and implications for human disease. Diabetes Metab Res Rev 2009; 25:208-218.
26. Shao S, He F, Yang Y, Yuan G, Zhang M, Yu X. Th17 cells in type 1 diabetes. Cell Immunol 2012; 280:16-21.
27. Fierabracci A. Peptide immunotherapies in Type 1 diabetes: lessons from animal models. Curr Med Chem 2011; 18:577-586.
28. King AJ. The use of animal models in diabetes research. Br J Pharmacol 2012; 166:877-894.
29. Lukić ML, Stosić-Grujicić S, Shahin A. Effector mechanisms in low-dose streptozotocin-induced diabetes. Dev Immunol 1998; 6:119-128.
30. Yaochite JN, Caliari-Oliveira C, Davanso MR etal. Dynamic changes of the Th17/Tc17 and regulatory T cell populations interfere in the experimental autoimmune diabetes pathogenesis. Immunobiology 2013; 218:338-352.
31. Reddy S, Wu D, Elliott RB. Low dose streptozotocin causes diabetes in severe combined immunodeficient (SCID) mice without immune cell infiltration of the pancreatic islets. Autoimmunity 1995; 20:83-92.
32. Kawasaki E, Abiru N, Eguchi K. Prevention of type 1 diabetes: from the view point of beta cell damage. Diabetes Res Clin Pract 2004; 66:S27-32.
33. Luo B, Chan WF, Lord SJ etal. Diabetes induces rapid suppression of adaptive immunity followed by homeostatic T-cell proliferation. Scand J Immunol 2007; 65:22-31.
34. Gaulton GN, Schwartz JL, Eardley DD. Assessment of the diabetogenic drugs alloxan and streptozotocin as models for the study of immune defects in diabetic mice. Diabetologia 1985; 28:769-775.
35. Koulmanda M, Qipo A, Auchincloss H Jr, Smith RN. Effects of streptozotocin on autoimmune diabetes in NOD mice. Clin Exp Immunol 2003; 134:210-216.